{
  "ticker": "GSS",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971298",
  "id": "02971298",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250722",
  "time": "0843",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250722/pdf/06m0fhnppqrjwm.pdf",
  "summary": "### **Material Information Summary (Quarterly Report - Appendix 4C)**  \n\n#### **Operational & Financial Highlights:**  \n- **Revenue**: $4.4M (Q4 FY2025, +52% QoQ, flat YoY).  \n- **US Market Progress**: Slow sales cycle due to customer internal delays; post-quarter signing of a contract with a major US healthcare system (revenue expected immaterial in Y1).  \n- **Cash Balance**: **$30.9M** (unchanged from prior quarter; 5.2 quarters of funding at current burn rate).  \n- **Cash Flow**: Net operating outflow of **$5.9M** (increased inventory for seasonal demand).  \n- **Strategic Initiatives**: Restructured US/EMEA teams, automated high-throughput diagnostic solution in development via partnership with Tecan Group.  \n\n#### **Key Risks/Challenges:**  \n- **US Delays**: Prolonged sales conversions due to macro uncertainty and workflow preferences.  \n- **Cash Burn**: Sustained operating outflows (~$6M/quarter); liquidity coverage down to ~5 quarters.  \n\n**No capital raising, dividends, or material M&A disclosed.**  \n\n*(Omitted: Director names, conference details, non-material partnerships.)*",
  "usage": {
    "prompt_tokens": 5165,
    "completion_tokens": 261,
    "total_tokens": 5426,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-21T22:59:25.786552"
}